Wu-Chou Su
Overview
Explore the profile of Wu-Chou Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
254
Citations
11544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Liao B, Subramaniam S, Chiu C, Mersiades A, Ho C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100771.
PMID: 39877028
Introduction: -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed...
2.
Sands J, Ahn M, Lisberg A, Cho B, Blumenschein Jr G, Shum E, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401349.
PMID: 39761483
Purpose: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety...
3.
Wang M, Xu Y, Huang W, Su W, Gao B, Lee C, et al.
Lung Cancer
. 2024 Dec;
199:108053.
PMID: 39647463
Background: Multiple agents can be used to treat patients with EGFR mutated non-small cell lung cancer (NSCLC) who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome...
4.
Blechter B, Hsiung C, Wang X, Zhang H, Seow W, Shi J, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581378
We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the EGFR gene in 998 East Asian never-smoking female LUAD...
5.
Hwu J, Panja A, Tsay S, Huang W, Lin S, Yeh C, et al.
Org Lett
. 2024 Nov;
26(46):9865-9870.
PMID: 39540692
An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the...
6.
Liao B, Chiang N, Chang G, Su W, Luo Y, Chong I, et al.
JCO Glob Oncol
. 2024 Sep;
10:e2400125.
PMID: 39348626
Purpose: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS...
7.
Hung C, Wu S, Yao C, Yeh H, Lin C, Chu C, et al.
Nat Commun
. 2024 Sep;
15(1):7885.
PMID: 39251588
The IL6-GP130-STAT3 pathway facilitates lung cancer progression and resistance to tyrosine kinase inhibitors. Although glycosylation alters the stability of GP130, its effect on the ligand IL6 remains unclear. We herein...
8.
Yang Y, Hu M, Zeng Y, Tseng Y, Chen Y, Su W, et al.
Cell Death Dis
. 2024 Aug;
15(8):629.
PMID: 39191727
No abstract available.
9.
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Park J, Feng Y, Su W, Oh D, Keam B, Shen L, et al.
BMC Cancer
. 2024 Aug;
24(1):1006.
PMID: 39138436
Background: FGFR genomic aberrations occur in approximately 5-10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecological, and...
10.
Boyer M, Hui R, Urban D, Clingan P, Su W, Devaux C, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1250.
PMID: 39054462
Background: The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygenase 1...